Altogether, these data highly suggest that Rosiglitazone, a PPARγ agonist and a known peroxisome proliferator, as previously discussed [37], could be used to enhance peroxisome activity in MCF-7 breast cancer cells and potentially reduce their stemness profile. The gene discussed is PPARG; the disease is breast carcinoma.